TYK Medicines and WuXi STA Launch Comprehensive Strategic Cooperation

TYK Medicine TY-2699a —The CDK7 inhibitorapproved by CDE to conduct clinical trial

TYK Medicines receives CDE Conditional Market Authorization for TY-9591

TYK Medicines TY-4028 —The EGFR/HER2 tyrosine kinase inhibitor approved by FDA to conduct the clinical trial

TYK Medicines will present the research progress and results of 6 innovative drug projects at the 2023 Annual Meeting of American Association for Cancer Research (AACR 2023)

TYK Medicine TY-2699a —The first CDK7 inhibitor in China approved by FDA to conduct clinical trial

TYK Medicine TY-2699a —The first CDK7 inhibitor in China approved by FDA to conduct clinical trial